Cargando…

Case Report: Subacute thyroiditis after receiving inactivated SARS-CoV-2 vaccine (BBIBP-CorV)

BACKGROUND: Subacute thyroiditis, an inflammatory disease, has been reported caused by vaccines in rare cases. In the context of the coronavirus disease 19 pandemic, various SARS-CoV-2 vaccines have been developed and may be potential triggers for subacute thyroiditis. CASE PRESENTATION: We report a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pi, Linhua, Lin, Jian, Zheng, Ying, Wang, Zhen, Zhou, Zhiguang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355607/ https://www.ncbi.nlm.nih.gov/pubmed/35935798 http://dx.doi.org/10.3389/fmed.2022.918721

Ejemplares similares

BBIBP-CorV/tozinameran: Subacute thyroiditis: 2 case reports
Publicado: (2022)

BBIBP-CorV: Hepatitis: case report
Publicado: (2022)

Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
por: Wang, Hui, et al.
Publicado: (2020)

BBIBP-CorV: Anterior uveitis: case report
Publicado: (2022)

Immune response and homeostasis mechanism following administration of BBIBP-CorV SARS-CoV-2 inactivated vaccine
por: Yin, Jianhua, et al.
Publicado: (2022)

Guillain-Barré Syndrome Following the First Dose of Inactivated SARS-CoV-2 Vaccine, BBIBP-CorV
por: Wijekoon, Lanka, et al.
Publicado: (2023)

Persistence of immune responses to the Sinopharm/BBIBP‐CorV vaccine
por: Jeewandara, Chandima, et al.
Publicado: (2022)

BBIBP-CorV: Steven-Johnson syndrome : case report
Publicado: (2022)

BBIBP-CorV: Acute disseminated encephalomyelitis: case report
Publicado: (2022)

BBIBP-CorV: Stevens-Johnson syndrome: case report
Publicado: (2022)

BBIBP-CorV: Stevens-Johnson-syndrome: case report
Publicado: (2022)

Vaccination with the Inactivated Vaccine (Sinopharm BBIBP-CorV) Ensures Protection against SARS-CoV-2 Related Disease
por: Wang, Chao, et al.
Publicado: (2022)

BBIBP-CorV/SARS-COV-2-vaccine-inactivated-Sinovac-Biotech: Eye disorders: 7 case reports
Publicado: (2022)

BBIBP-CorV Vaccination against the SARS-CoV-2 Virus Affects the Gut Microbiome
por: Shen, Yang, et al.
Publicado: (2023)

SARS-CoV-2 antibody response after BBIBP-CorV (Sinopharm) vaccination in cancer patients: A case-control study
por: Safarnezhad Tameshkel, Fahimeh, et al.
Publicado: (2023)

SARS-CoV-2-specific T Cell Immunity after Vaccination with Sputnik V and BBIBP-CorV
por: Babrukevich, Darya, et al.
Publicado: (2022)

Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people
por: Rouco, Santiago Oviedo, et al.
Publicado: (2022)

BBIBP-CorV: Adult multisystem inflammatory syndrome: case report
Publicado: (2021)

BBIBP-CorV: Eye disorders and hypertension: 7 case reports
Publicado: (2021)

BBIBP-CorV/SARS-COV-2-vaccine-inactivated-Sinovac-Biotech: Cerebral venous thrombosis: 4 case reports
Publicado: (2022)

Neutralization of five SARS-CoV-2 variants of concern by convalescent and BBIBP-CorV vaccinee serum
por: Zhu, Yuqi, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 omicron after BBIBP-CorV and ZF2001 booster vaccination
por: Zhang, Yuwei, et al.
Publicado: (2023)

Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals
por: Mallah, Saad I., et al.
Publicado: (2023)

BBIBP-CorV: Vaccine-induced immune thrombotic thrombocytopenia: case report
Publicado: (2022)

Thrombotic thrombocytopenia After Sinopharm BBIBP‐CorV COVID‐19 vaccination
por: Hosseinzadeh, Rezvan, et al.
Publicado: (2022)

Antibody responses to Sinopharm/BBIBP-CorV in pregnant mothers in Sri Lanka
por: Jeewandara, Chandima, et al.
Publicado: (2022)

Evaluation of SARS-CoV-2 Serum Level in Patients Vaccinated With Sinopharm/BBIBP-CorV With Kidney Transplantation
por: Rahbar, Maryam, et al.
Publicado: (2022)

Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2
por: Badano, María Noel, et al.
Publicado: (2022)

Association of Homologous and Heterologous Vaccine Boosters With SARS-CoV-2 Infection in BBIBP-CorV Vaccinated Healthcare Personnel
por: Park, Sungsoo, et al.
Publicado: (2022)

Post-vaccination seropositivity against SARS-CoV-2 in peruvian health workers vaccinated with BBIBP-CorV (Sinopharm)
por: Cvetkovic-Vega, Aleksandar, et al.
Publicado: (2023)

Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2
por: Huang, Baoying, et al.
Publicado: (2021)

Abducense nerve palsy following BBIBP-CorV (Sinopharm) COVID-19 vaccine
por: Khalili, M.R., et al.
Publicado: (2022)

Correlation of gut microbiota and metabolic functions with the antibody response to the BBIBP-CorV vaccine
por: Tang, Bo, et al.
Publicado: (2022)

Cord blood antibodies following BBIBP‐CorV (Sinopharm) vaccination during pregnancy
por: Hantoushzadeh, Sedigheh, et al.
Publicado: (2023)

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
por: Xia, Shengli, et al.
Publicado: (2021)

A Cohort Study on the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients With Breast Cancer; Does Trastuzumab Interfere With the Outcome?
por: Joudi, Maryam, et al.
Publicado: (2022)

Persistence of antibody and T cell responses to the Sinopharm/BBIBP-CorV vaccine in Sri Lankan individuals
por: Jeewandara, Chandima, et al.
Publicado: (2021)

Evaluation of the Efficacy of BBIBP-CorV Inactivated Vaccine Combined with BNT62b2 mRNA Booster Vaccine
por: Rákóczi, Éva, et al.
Publicado: (2023)

Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern
por: Yu, Xiaoqi, et al.
Publicado: (2022)

Heterologous BBIBP-CorV/ZF2001 vaccination augments neutralization against SARS-CoV-2 variants: A preliminary observation
por: Zhao, Yingze, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_htej25e89cpm8cc8jacnjtorjd